The European Commission announced on Thursday that Israeli drug-maker Teva is being investigated by EU antitrust regulators over whether it illegally hindered rivals’ access to its multiple sclerosis medicine Copaxone, Reuters reports.
According to the announcement, the probe will look into whether Teva has abused its dominant market position in breach of EU antitrust rules, which could lead to hefty fines.
Read more